Eurobio Oncology
EndoPredict® App
Explore How EndoPredict® Works – With Our Interactive
Animation App
Our interactive EndoPredict app illustrates the functional principle behind the EndoPredict test in a clear and engaging way. EndoPredict combines a molecular fingerprint – the 12-Gene Molecular Score derived from gene expression within the tumor – with key clinical factors (tumor size and lymph node status) to calculate the EPclin Risk Score.1 This comprehensive score helps guide treatment decisions in early-stage ER+/HER2– breast cancer.
- Adjust gene expression levels using sliders to simulate different molecular profiles.
- Set clinical parameters such as tumor size and nodal status.
- Visualize the resulting risk over time - displayed as continuous curves for:
- 10-year risk of distant recurrence1
- Estimated chemotherapy benefit at 10 years2
- Risk between years 5 and 153
By modifying the gene expression sliders, you can see how each component contributes to the overall risk score.
Tip: Double-click the lock symbol to unlock and adjust the 12-Gene Molecular Score directly.
Click below to launch the animation and explore how molecular and clinical data come together in EndoPredict.
EndoPredict® Testing – Fast, Local, Reliable
The EndoPredict prognostic and predictive breast cancer test is performed in certified local laboratories, delivering reliable results within just a few days.
Physicians can conveniently order EndoPredict through a wide network of participating labs.
Use the link below to find a local lab and place your order. Have questions? Contact us anytime – we’re here to help.
References
- Filipits M. et al.: A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds IndependentInformation to Conventional Clinical Risk Factors. Clin. Cancer Res. 2011
- Sestak I. et al.: Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. 2019
- Filipits M. et al.: Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node- Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. Clin Cancer Res. 2019
